Abstract
Fibroblast growth factor 21 (FGF21) is emerging as a key regulator of energy homeostasis and presents a novel target for the development of therapies for the treatment of diabetes, cardiovascular disease and obesity. Recent publications have demonstrated that FGF21 resides downstream of a complex network of transcriptional regulators which modulate its expression in response to a wide array of physiological stimuli or pharmacologic agents. The manner in which these mechanisms are integrated to regulate FGF21 transcription, production and subsequent secretion is poorly understood. While FGF21 is detected in many metabolically active tissues and is regulated by several of the known transcription factors involved in metabolic control little is known about how these pathways are integrated. In this review, we discuss the data presented to date on regulation of FGF21 by a wide array of transcription factors and explore how it relates to metabolic regulation in vivo.
Keywords: FGF21, metabolism, expression regulation, homeostasis, transcription, metabolic, stimuli, metabolic regulation, obesity, pharmacologic agents
Current Diabetes Reviews
Title:FGF21: The Center of a Transcriptional Nexus in Metabolic Regulation
Volume: 8 Issue: 4
Author(s): A. C. Adams and A. Kharitonenkov
Affiliation:
Keywords: FGF21, metabolism, expression regulation, homeostasis, transcription, metabolic, stimuli, metabolic regulation, obesity, pharmacologic agents
Abstract: Fibroblast growth factor 21 (FGF21) is emerging as a key regulator of energy homeostasis and presents a novel target for the development of therapies for the treatment of diabetes, cardiovascular disease and obesity. Recent publications have demonstrated that FGF21 resides downstream of a complex network of transcriptional regulators which modulate its expression in response to a wide array of physiological stimuli or pharmacologic agents. The manner in which these mechanisms are integrated to regulate FGF21 transcription, production and subsequent secretion is poorly understood. While FGF21 is detected in many metabolically active tissues and is regulated by several of the known transcription factors involved in metabolic control little is known about how these pathways are integrated. In this review, we discuss the data presented to date on regulation of FGF21 by a wide array of transcription factors and explore how it relates to metabolic regulation in vivo.
Export Options
About this article
Cite this article as:
C. Adams A. and Kharitonenkov A., FGF21: The Center of a Transcriptional Nexus in Metabolic Regulation, Current Diabetes Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/157339912800840505
DOI https://dx.doi.org/10.2174/157339912800840505 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Vancoplus Versus Ceftriaxone Against Cephalosporin Resistance MRSA Strain in Experimental Meningitis Model
Cardiovascular & Hematological Disorders-Drug Targets Gallium-68 Based Positron Emission Tomography (PET) Probes for Myocardial Perfusion Imaging
Current Medical Imaging Advanced Techniques for Penetration Enhancement in Transdermal Drug Delivery System
Current Drug Delivery Recent Developments in Female Hormonal Contraception
Current Women`s Health Reviews Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Metabolomics of Serum Peptides
Protein & Peptide Letters Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry Fc-independent Phagocytosis: Implications for IVIG and other Therapies in Immune-mediated Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Monitoring of Plasma Digoxin for COVID-19 Patients Using a Simple UPLC-MS/MS Method
Current Pharmaceutical Analysis The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Mitochondrial Functionality and Chemical Compound Action on Sperm Function
Current Medicinal Chemistry Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery Dietary Polyphenols and Type 2 Diabetes: Current Insights and Future Perspectives
Current Medicinal Chemistry Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes
Current Drug Targets